US 12,221,434 B2
Sulfonamide carboxamide compounds
Matthew Cooper, Cambridge (GB); David Miller, Cambridge (GB); Angus Macleod, Cambridge (GB); Stephen Thom, Nottingham (GB); Jonathan Shannon, Nottingham (GB); and Jokin Carrillo Arregui, Nottingham (GB)
Assigned to INFLAZOME LIMITED, Dublin (IE)
Appl. No. 16/762,000
Filed by Inflazome Limited, Dublin (IE)
PCT Filed Nov. 9, 2018, PCT No. PCT/EP2018/080739
§ 371(c)(1), (2) Date May 6, 2020,
PCT Pub. No. WO2019/092171, PCT Pub. Date May 16, 2019.
Claims priority of application No. 1718563.8 (GB), filed on Nov. 9, 2017; application No. 1721726.6 (GB), filed on Dec. 22, 2017; application No. 1721736.5 (GB), filed on Dec. 22, 2017; application No. 1810983.5 (GB), filed on Jul. 4, 2018; and application No. 1813283.7 (GB), filed on Aug. 15, 2018.
Prior Publication US 2020/0354341 A1, Nov. 12, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 403/06 (2006.01); C07D 401/04 (2006.01); C07D 403/12 (2006.01); C07D 417/04 (2006.01); C07D 417/12 (2006.01)
CPC C07D 403/06 (2013.01) [C07D 401/04 (2013.01); C07D 403/12 (2013.01); C07D 417/04 (2013.01); C07D 417/12 (2013.01)] 19 Claims
 
1. A compound of formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt or solvate thereof, wherein:
Q is selected from O or S;
R1 is a 5-membered heteroaryl group substituted with at least one group RX, wherein the 5-membered heteroaryl group of R1 contains at least one nitrogen atom in the 5-membered ring structure, wherein RX is any monovalent group comprising a heteroaryl group, and wherein the 5-membered heteroaryl group of R1 may optionally be further substituted; and
R2 is a cyclic group substituted at the α and α′ positions relative to the point of attachment of the cyclic group to the remainder of the molecule, wherein R2 may optionally be further substituted;
provided that the compound is not:

OG Complex Work Unit Chemistry